What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2336.png

24-hr control

 

ESC 2024 guidelines promote the use of out-of-office measurement (ambulatory monitoring - usually for a 24-h period) for diagnosis and ongoing management of hypertension.1


Valsartan has demonstrated consistent 24-hour efficacy, including during critical early morning hours when cardiovascular risk peaks.2

 

 

The BP control is essential

Poor control of blood pressure resulting in changes to antihypertensive drugs also affects variability. Long term variability in blood pressure measured in adults at clinic visits is associated with cardiovascular and mortality outcomes.3

 

Group 2465.gif
Group 2437.png

Mean±SD decreases from baseline in 24-hour, daytime, and nighttime systolic blood pressure obtained on ambulatory blood pressure monitoring after 2 and 8 weeks of treatment with olmesartan and valsartan.2

slide 4-1.gif

Reference 2

Twenty-four-hour systolic and diastolic blood pressure at baseline and after 2 and 8 weeks of treatment with valsartan.2

slide 4-2.gif

Reference 2

*P<.001 vs baseline; †P<.001 vs olmesartan; ‡P<.01 vs olmesartan

Study design

Single-pill combinations (SPCs) are recommended by major hypertension guidelines, including the ESC1 and ESH7, for patients requiring multi-drug therapy.

 

SPCs simplify treatment regimens, improve adherence, and accelerate blood pressure control. Clinical evidence shows that patients on SPCs achieve target BP faster and with greater consistency compared to multi-pill regimens.1

Group 2420.png

Reduce pill burden1

Group 2419.png

 Improve adherence1

Group 2418.png

BP-lowering treatment of resistant hypertension1

Group 2464.png


ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, renin- angiotensin system.

References

  1. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Aug 30;45(38):3912-4018.

  2. Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Advances in therapy. 2005 Jan;22:32-43.

  3. Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. bmj. 2016 Aug 9;354.

  4. Egyptian drug authority Co-Tareg approved leaflet; approval date: 8/5/2025.

  5. Egyptian drug authority Exforge approved Leaflet; approval date: 4/5/2025.

  6. Egyptian drug authority Exforge-HCT Leaflet; approval date: 4/5/2025.

  7. Mancia Chairperson G, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Eae A, Azizi M, Benetos A. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). Journal of hypertension. 2023;41(12):1874-2071.
     

Approved by Egyptian Drug Authority: HF0082OA4758/102025. Invalidation date: 14/10/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.

Valsartan QR.jpeg

HF0082OA4758/102025 14/10/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting